<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380142</url>
  </required_header>
  <id_info>
    <org_study_id>M15-736</org_study_id>
    <secondary_id>2019-003930-18</secondary_id>
    <nct_id>NCT04380142</nct_id>
  </id_info>
  <brief_title>Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse
      over time, but how quickly it progresses varies a lot from person to person. Some symptoms of
      PD are tremors, stiffness, and slowness of movement. This study measures the efficacy,
      safety, and tolerability of ABBV-951 versus oral Levodopa (LD)/Carbidopa (CD) [LD/CD] in
      advanced PD participants to achieve reduction in motor fluctuations.

      ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa
      Phosphate (LDP/CDP) given subcutaneously (under the skin) for the treatment of Parkinson's
      Disease. The study has two treatment arms . In one arm, participants will be given ABBV-951
      plus oral placebo (does not contain treatment drug). In the second arm, participants will be
      given placebo solution and LD/CD tablets. Adult participants with advanced PD will be
      enrolled. Approximately 130 participants will be enrolled in the study in approximately 80
      sites across the world.

      In one arm, participants will receive ABBV-951 solution as a continuous infusion under the
      skin plus oral placebo capsules for LD/CD. In the second arm, participants will receive
      placebo solution for ABBV-951 as a continuous infusion under the skin plus oral capsules
      containing LD/CD tablets. The treatment duration is 12 weeks.

      There may be higher treatment burden for participants in this trial compared to their
      standard of care. Participants will attend regular visits during the course of the study at a
      hospital or clinic. The effect of the treatment will be checked by medical assessments, blood
      tests, checking for side effects, and completing questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">February 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in &quot;On&quot; Time (Hours) Without Troublesome Dyskinesia</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>&quot;On&quot; time without dyskinesia plus &quot;On&quot; time with non-troublesome dyskinesia are based on the Parkinson's Disease (PD) Diary (normalized to a 16-hour waking day averaged over 3 consecutive days). Baseline value is defined as the average of normalized &quot;On&quot; time without troublesome dyskinesia collected over the 3 PD Diary days before randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in &quot;Off&quot; Time (Hours)</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>&quot;Off&quot; time is assessed by the PD Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Motor Experiences of Daily Living</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>Motor Experiences of Daily Living is assessed by Part II of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The Part II MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Symptoms</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>Sleep symptoms are assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2). The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessed by PD Questionnaire-39 item (PDQ-39)</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>PDQ-39 is a disease-specific instrument designed to measure aspects of health that are relevant to subjects with PD, and which may not be included in general health status questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Morning &quot;Off&quot; Status</measure>
    <time_frame>At Week 12</time_frame>
    <description>Early morning &quot;Off&quot; status is assessed by the PD Diary as percentage of participants with early morning &quot;Off&quot; upon waking up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessed by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>EQ-5D-5L is a standardized instrument developed by the EuroQol Group as a measure of health related quality of life that can be used in a wide range of health conditions and treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD Symptoms as Assessed by the MDS-UPDRS Tool Part I</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD Symptoms as Assessed by the MDS-UPDRS Tool Part III</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD Symptoms as Assessed by the MDS-UPDRS Tool Part IV</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD Symptoms as Assessed by the MDS-UPDRS Tool Total Score of Parts I - III</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD Symptoms as Assessed by the Parkinson's KinetiGraph/Personal KinetiGraph (PKG) Wearable Device</measure>
    <time_frame>Baseline (Week 0) Up to Week 12</time_frame>
    <description>PKG wearable device is an innovative mobile health technology that provides continuous, objective, ambulatory assessment of the symptoms of PD including tremor, bradykinesia, dyskinesia, and daytime somnolence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Parkinson's Disease (PD)</condition>
  <arm_group>
    <arm_group_label>ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-951</intervention_name>
    <description>Solution for continuous subcutaneous infusion (CSCI)</description>
    <arm_group_label>ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Levodopa/Carbidopa (LD/CD)</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Carbidopa (LD/CD)</intervention_name>
    <description>Oral encapsulated tablet</description>
    <arm_group_label>Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-951</intervention_name>
    <description>Solution for continuous subcutaneous infusion (CSCI)</description>
    <arm_group_label>Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive.

          -  Participants must be taking a minimum of 400 milligrams/day (mg/day) of Levodopa (LD)
             equivalents and be judged by the investigator to have motor symptoms inadequately
             controlled by current therapy, have a recognizable/identifiable &quot;Off&quot; and &quot;On&quot; states
             (motor fluctuations), and have an average &quot;Off&quot; time of at least 2.5 hours/day over 3
             consecutive PD Diary days with a minimum of 2 hours each day.

          -  Participant or caregiver, if applicable, demonstrates the understanding and correct
             use of the delivery system, including the insertion of the cannula into the
             participant's abdomen, as assessed by the investigator or designee during the
             Screening period.

        Exclusion Criteria:

          -  Clinically significant, unstable medical conditions or any other reason that the
             investigator determines would interfere with the participant's participation in this
             study or would make the participant an unsuitable candidate to receive study drug.

          -  History of allergic reaction or significant sensitivity to LD or constituents of the
             study drug (and its excipients) and/or other products in the same class.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - Main /ID# 216595</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama /ID# 216757</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604-3302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenoscience, Inc /ID# 217110</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muhammad Ali Parkinson Center /ID# 216566</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013-4407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth Neurology/Phoenix Neurological Associates /ID# 216642</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018-2111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Movement Disorders Center of Arizona /ID# 216503</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Res Inst /ID# 216507</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences /ID# 216501</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's and Movement /ID# 216705</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center /ID# 216551</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San /ID# 216598</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical /ID# 216500</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Net /ID# 216970</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 216674</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Institute and Clinical Center - Mountainview /ID# 216768</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040-4106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Med /ID# 216726</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center - West Hollywood /ID# 216561</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hosp /ID# 216527</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center /ID# 216637</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301-1880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Neurological Research, LLC /ID# 216784</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210-7009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center /ID# 216737</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113-2736</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Service /ID# 216515</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital /ID# 216632</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Moveme /ID# 216517</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research /ID# 217089</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Hull Rd /ID# 216514</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network - Miami /ID# 216679</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research /ID# 216765</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates Ormond Beach /ID# 216521</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research /ID# 216525</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute /ID# 216552</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243-3956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 216638</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology /ID# 217207</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-3209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Res /ID# 217091</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurological Center of North Georgia /ID# 216499</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center /ID# 216567</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical /ID# 217187</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University (SIU) Medicine /ID# 216721</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702-4933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Clinical Research Cent /ID# 216615</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Kansas Med Ctr /ID# 216528</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University /ID# 217158</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Partners /ID# 216510</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55130-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals - Chesterfield /ID# 216669</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005-1205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hosp. of Kansas Cit /ID# 216633</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 216548</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Nebraska Med Ctr /ID# 216497</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Neurosciences Institute /ID# 217875</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648-2300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Great Neck /ID# 216833</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021-5206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel /ID# 216712</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester /ID# 218737</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research Inc. /ID# 216596</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612-8106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Univ HS /ID# 216522</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Wexner Medical Center /ID# 216900</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoNeuro - New Albany /ID# 217157</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054-8167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma /ID# 216860</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136-6378</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Research Institute /ID# 216558</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232-2003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania /ID# 216560</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital /ID# 216553</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health /ID# 216594</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615-3593</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Med Ctr /ID# 216675</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gill NeuroScience /ID# 216942</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerwin Research Center /ID# 216587</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas - LBJ Fwy /ID# 216564</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243-1188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Movement Disorder Specialist /ID# 216523</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626-7724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital /ID# 216707</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consul /ID# 216629</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care /ID# 216710</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research /ID# 216731</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates - Forest Ave /ID# 216636</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229-4913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience /ID# 216526</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-5788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research /ID# 221036</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202-1342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin /ID# 216498</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital /ID# 218681</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital /ID# 216535</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital /ID# 217512</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital /ID# 218373</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 216533</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Centre /ID# 216537</name>
      <address>
        <city>Cheltenham</city>
        <state>Victoria</state>
        <zip>3192</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital /ID# 216534</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 216536</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease (PD)</keyword>
  <keyword>ABBV-951</keyword>
  <keyword>Levodopa/Carbidopa (LD/CD)</keyword>
  <keyword>Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

